Since when is profitability a prerequisite for speculation? Find out why Cramer thinks you should get in on this stock.   Read More

Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.    Read More

GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu. In fact, it is the only company that has products on both sides. GSK makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago. And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter.    Read More

Cramer makes the call on viewers' favorite stocks.   Read More

The folks at Eli Lilly probably cringe every time I go here, but the company this morning reported that third quarter U.S. sales of the erectile dysfunction drug Cialis sprung 13 percent to nearly $159 million.    Read More

This Friday the CDC is expected to start giving weekly updates on where and how much H1N1 vaccine has been shipped. I'm curious what the demand will truly turn out to be. Some people are growing concerned about the increasing number of pediatric deaths from H1N1 and may rush to get their kids and themselves vaccinated. Others are afraid of or paranoid about the vaccine.    Read More

Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.    Read More

If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.   Read More

The CDC announced today that healthcare workers in Tennessee and Indiana would be amongst the first to get swine flu vaccinations.  The outbreak of the H1N1 swine flu virus has sadly killed over 3,900 peope per a report by the World Health Organization (WHO) on September 25th.  At the same time the race to battle the pandemic has propped up the shares of biotech companies that promise solutions.   Read More

The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.    Read More